医学
抗真菌
两性霉素B
加药
侵袭性念珠菌病
重症监护医学
药品
抗药性
分子诊断学
药理学
氟康唑
生物信息学
皮肤病科
微生物学
生物
作者
Daniel Z P Friedman,Ilan S. Schwartz
标识
DOI:10.1016/j.idc.2023.05.001
摘要
Recently, there have been significant advances in the diagnosis and management of invasive fungal infections. Compared with traditional fungal diagnostics, molecular assays promise improved sensitivity and specificity, the ability to test a range of samples (including noninvasive samples, ie, blood), the detection of genetic mutations associated with antifungal resistance, and the potential for a faster turnaround time. Antifungals in late-stage clinical development include agents with novel mechanisms of action (olorofim and fosmanogepix) and new members of existing classes with distinct advantages over existing antifungals in toxicity, drug-drug interactions, and dosing convenience (oteseconazole, opelconazole, rezafungin, ibrexafungerp, encochleated amphotericin B).
科研通智能强力驱动
Strongly Powered by AbleSci AI